The ONLY purpose of the parathyroid glands is to regulate the calcium level in our bodies within a very narrow range so that the nervous and muscular systems can function properly. This is all they do. They measure the amount of calcium in the blood every minute of every day... and if the calcium levels go down a little bit, the parathyroid glands recognize it and make parathyroid hormone (PTH) which goes to the bones and takes some calcium out (makes a withdrawal from the calcium vault) and puts it into the blood. When the calcium in the blood is high enough, then the parathyroids shut down and stop making PTH.
Very easy to order and fast delivery. Cant wait for the results
- Marco, Port Elizabeth
Gained 8kgs from the 8 week bulking cycle. - TJ, Johannesburg
Recieved my package the next day after ordering. Superb Service. - Samantha, Johannesburg ________________________________________________________________
I have just finished the Super Cut Cycle. Very pleased with the results, gained some muscle and strength and lost a decent amount of fat. - Ryan, Nelspruit ________________________________________________________________
Take my word for it this product works like it says it does ! Not only do I look better but I feel better. -Roodey, Kzn .
A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was months in the nab-paclitaxel-gemcitabine group as compared with months in the gemcitabine group (hazard ratio for death, ; 95% confidence interval [CI], to ; P<). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was months in the nab-paclitaxel-gemcitabine group, as compared with months in the gemcitabine group (hazard ratio for disease progression or death, ; 95% CI, to ; P<); the response rate according to independent review was 23% versus 7% in the two groups (P<). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.